Use the hyperlinks, where available to access additional clinical trial information.
A Phase I, Open-Label, Multi-Center, Dose Finding Study to Investigate the Safety, Pharmacokinetics, and Preliminary Efficacy of ATG-018 (ATR Inhibitor) Treatment in Patients With Advanced Solid Tumors and Hematological Malignancies
Antengene Discovery Limited
This is a dose escalation and expansion trial. Participants enrolled in the dose escalation cohort(s) will receive a single dose of ATG-018 monotherapy on Cycle 1 Day 1 (C1D1), followed by twice daily dosing from the morning dose on Cycle 1 Day 2. Subject(s) will receive intermittent dosing in a 3 days on/4 days off schedule in 21-day cycles until disease progression or unacceptable toxicity.